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ABSTRACT
A switching mechanism in gene expression, where
two genes are positively correlated in one condition
and negatively correlated in the other condition, is
a key to elucidating complex biological systems.
There already exist methods for detecting switching
mechanisms from microarrays. However, current
approaches have problems under three real cases:
outliers, expression values with a very small range
and a small number of examples. ROS-DET over-
comes these three problems, keeping the computa-
tional complexity of current approaches. We
demonstrated that ROS-DET outperformed existing
methods, under that all these three situations
are considered. Furthermore, for each of the top
10 pairs ranked by ROS-DET, we attempted to
identify a pathway, i.e. consecutive biological phe-
nomena, being related with the corresponding two
genes by checking the biological literature. In 8 out
of the 10 pairs, we found two parallel pathways, one
of the two genes being in each of the two pathways
and two pathways coming to (or starting with) the
same gene. This indicates that two parallel
pathways would be cooperatively used under one
experimental condition, corresponding to the
positive correlation, and the two pathways might
be alternatively used under the other condition,
corresponding to the negative correlation.
ROS-DET is available from http://www.bic.kyoto-u
.ac.jp/pathway/kayano/ros-det.htm.
INTRODUCTION
Gene expression analysis is a basic and important tech-
nique in molecular biology. There are two typical and
simple concepts for expression analysis: (i) differential
expression, which examines the difference in expression
for a single gene between different experimental condi-
tions (classes), such as case and control patients (1),
and (ii) coexpression, which focuses on a combination
of multiple genes, checking whether they are over- or
underexpressed simultaneously (2). One notion with
both of these two properties is differential co-expression,
in which coexpression patterns differ depending upon the
experimental conditions (3,4). We address an issue of
ﬁnding one type of differential coexpression, which here-
after we call a ‘switching mechanism’. The switching
mechanism has two experimental conditions for expres-
sion of two genes, where two genes are positively
correlated under one experimental condition while they
are negatively correlated under the other condition
(3,5–8). Figure 1 shows one simulated example of the
switching mechanism. A simple, well-known case of the
switching mechanism is Max, a transcription factor, which
plays a role of an activator or a suppressor, depending on
whether it binds to Myc (i.e. Myc-Max) or Mad (i.e.
Mad-Max) (9). Another case is thyroid hormone
receptor (TR), which forms a complex called TR-RXR
and can be also an activator or a suppressor, depending
on the absence or presence (amount) of thyroid hormone
(10). Finding the switching mechanisms would be a key
step to elucidating complex biological systems.
There are two typical techniques for ﬁnding switching
mechanisms: the absolute difference of two correlation
coefﬁcients (3,5–7) and interaction test (8). Interaction
test, being popular as a standard approach for detecting
epistasis in genetics (11), is the log-likelihood ratio test
between two logistic regressions with/without an inter-
action term. This test examines the strength of the inter-
action between two genes, which is in general equivalent
to checking whether two genes can take the switching
mechanism. However, a serious disadvantage of inter-
action test is its high computational burden, making it
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practically (8).
We then focus on the absolute difference of two correl-
ation coefﬁcients. The procedure of this approach is that
we ﬁrst compute the correlation coefﬁcient of two genes in
expression for each of the two experimental conditions
and check the absolute difference of the two correlation
coefﬁcients. More concretely, in Figure 1, we ﬁrst compute
the correlation coefﬁcient r1 between gene X and gene Y
for one experimental condition, say class 1 (shown by+),
and r2 between them for the other condition, say class 2
(shown by  ). We then compute the absolute difference
between these two correlation coefﬁcients as the score of
two genes X and Y as shown below:
sðX;YÞ¼j r1   r2jð 1Þ
A switching mechanism must have this of a larger value,
because two correlation coefﬁcients should be different
in the switching mechanism. We can consider any
measure of correlation coefﬁcients in this approach, such
as the Pearson’s correlation coefﬁcient (5,7) and the
Spearman’s rank correlation (6) [(3) is a review over dif-
ferential coexpression, including the switching mechan-
ism]. Because of various correlation coefﬁcients, there
can be many approaches of using the absolute difference
of two correlation coefﬁcients, but they still have problems
by which negative cases can be detected as positives. The
negatives which can be detected incorrectly are caused by
the following three main reasons: (i) outliers, (ii) range
bias and (iii) a small number of examples. Figure 2a illus-
trates a typical negative case of (i), where only two points
of class 2 are in the upper-right area, which are outliers
and make this case pretend to be a switching mechanism.
Figure 2b shows a case of (ii), where the range of expres-
sion values of class 2 is much smaller than that by class 1.
Regardless of the very small range, class 2 can show a
strong negative correlation in its ﬁgure, by which the
absolute difference between the two correlation coefﬁ-
cients would become large. In reality, however, the small
range of class 2 makes us unconvincing whether class 2 is
negatively correlated or not. Thus, we cannot say that
Figure 2b is a switching mechanism, and this means that
Figure 2b should be a negative case. Figure 2c shows
a typical case of (iii), where the number of points in
two classes is so small that it cannot be considered as a
switching mechanism, implying that this cannot be a
positive gene pair.
We propose a method, which we call ROS-DET
(standing for RObust Switching mechanisms DETector)
to avoid detecting the negative cases as positives (or to
reduce the so-called false positive rates) in the paradigm
of the absolute difference of two correlation coefﬁcients.
First, ROS-DET uses a robust measure of correlation co-
efﬁcient, so-called biweight midcorrelation (12), to avoid
detecting gene pairs with outliers such as Figure 2a as
switching mechanisms. Most typical correlation coefﬁ-
cients robust against outliers are the Spearman’s and
Kendall rank correlations, but they use the ranking
after sorting all the given values, which might lose some
information in the original values. On the other hand, the
biweight midcorrelation is a modiﬁcation of the Pearson’s
correlation coefﬁcient which allows to keep the original
values and consider outliers carefully. The biweight
midcorrelation was thus used in microarray data
analysis already for detecting coexpression gene pairs
(13), and the performance advantage of the biweight
midcorrelation in expression analysis over other correl-
ation coefﬁcients was already shown (14). Second,
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Figure 2. Three types of negative cases of switching mechanisms.
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Figure 1. A sample of switching mechanisms with two classes (shown
by plus symbol and ﬁlled square).
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cients by a weight, which reﬂects upon the range bias
between two classes so that the weight becomes smaller
as the range bias increases. This means that the absolute
difference of correlation coefﬁcients is lowered by the
weight more as the range bias is larger. Third,
ROS-DET uses P-values to discard gene pairs with only
a small number of examples even if their weighted
absolute difference of correlation coefﬁcients is large.
We use hypothesis testing to check the equality of
biweight midcorrelation coefﬁcients derived from two
experimental conditions, meaning that gene pairs with
higher P-values are more insigniﬁcant in difference of
two biweight midcorrelation coefﬁcients. On the whole,
ROS-DET has two steps: WCOR (sorting gene pairs by
the Weighted absolute difference between two biweight
midCORrelation) and ECOR (the hypothesis testing on
the Equality of two biweight midCORrelation). All gene
pairs, which are generated from a given expression
dataset, are ﬁrst ranked by the weighted difference of
two biweight midcorrelations in WCOR, and if P-values
of gene pairs are high in ECOR, they are then deleted.
We experimentally conﬁrmed the effectiveness of
ROS-DET through experiments with synthetic and real
datasets. We ﬁrst generated synthetic datasets to
examine the performance of WCOR on two problems,
i.e. outliers and range bias, comparing to existing
approaches. The results showed that WCOR outper-
formed all the other competing methods. We then
checked the effectiveness of ECOR by using real data con-
sisting of over 2.60 10
10 gene combinations generated
from 46 datasets in Gene Expression Omnibus (GEO).
The result showed that removing gene pairs with high
P-values relaxed the bias to the data with a smaller
number of examples. Finally, we focused on the top 10
gene pairs in the ﬁnal output of ROS-DET, to check the
biological relevance of each pair. For 8 out of the 10 pairs,
we found two (parallel) pathways, which start with or
come to the same gene and, for each pair, have one of
two genes at each pathway separately. The parallel
pathways imply that two parallel pathways might be co-
operatively used under one experimental condition, cor-
responding to the positive correlation of two genes, and
the two pathways might be alternatively used under the
other condition, corresponding to the negative correlation
of two genes.
In summary, the main contribution of this article can
be the following three: (i) we have developed ROS-DET
based on the weighted midcorrelation coefﬁcients,
(ii) empirically validated the performance of ROS-DET
and (iii) applied ROS-DET to real data to ﬁnd new gene
pairs with switching mechanisms.
MATERIALS AND METHODS
The main input of ROS-DET is an expression dataset
measured under two experimental conditions, and the
output is gene pairs with switching mechanisms between
two experimental conditions. ROS-DET ﬁrst generates all
possible gene pairs from a given dataset and the following
two steps are run over all pairs: (i) WCOR: all gene pairs
are sorted by the weighted absolute difference of biweight
midcorrelation coefﬁcients and (ii) ECOR: out of the
sorted gene pairs, pairs with high P-values regarding the
equality of two biweight midcorrelation coefﬁcients
are removed. The feature of WCOR is biweight mid-
correlation coefﬁcient and the weighted absolute differ-
ence of two correlation coefﬁcients, while that of ECOR
is hypothesis testing on the equality of two biweight
midcorrelation coefﬁcients. Below, we explain each of
the three features in detail and ﬁnally show the entire pro-
cedure of our approach.
Preliminaries
Let D be a given (microarray expression) dataset with
G genes and two classes C1 and C2 (with N1 and N2
examples, respectively) corresponding to the two experi-
mental conditions. We consider all possible pairs of genes
over G genes. Let X and Y be two genes of an arbitrary
pair. Let xi be the expression value of gene X for an
example i and similarly yi be that of gene Y for i. Let
mx,k be the median of expression values in class Ck for
gene X, and my,k be that for gene Y. Furthermore, let
dx,k be the sample median of Wxi mx,kW over all values xi
satisfying i2Ck, and dy,k be that of Wyi my,kW over all yi
where i2Ck. Let r1 and r2 be correlation coefﬁcients for
C1 and C2, respectively. When we already know the true
value of the correlation coefﬁcient, we write the true cor-
relation coefﬁcients by  1 and  2 for C1 and C2, respect-
ively. For example, in order to generate synthetic data,
we can use  1 and  2.
WCOR: biweight midcorrelation
The biweight midcorrelation rk (12) for class Ck between
two genes X and Y can be given as follows:
rk ¼
X
i2Ck
wðuiÞwðviÞðxi   mx;kÞðyi   my;kÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X
i2Ck
w2ðuiÞðxi   mx;kÞ
2
()
X
i2Ck
w2ðviÞðyi   my;kÞ
2
() v u u t
;
where
wðzÞ¼ð 1   z2Þ
2 if jzj 1
¼ 0 otherwise;
ui=(xi mx,k)/(K   dx,k) and vi=(yi my,k)/(K   dy,k).
[K was set at nine in our experiments, according to
(12,15,16).] Here
P
i2Ck w2ðuiÞðxi   mx;kÞ
2 can be
normalized into the ‘biweight midvariance’ (12), which is
given in the Supplementary Data and hereafter we write
by qx,k. Similarly, we can write qy,k for the biweight
midvariance of gene Y. We note that if weights w(ui)
and w(vi) are always both 1 over all i and medians mx,k
and my,k are both the means (denoted by x,k and y,k,
respectively), then rk is exactly the same as the Pearson’s
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rk ¼
P
i2Ckðxi    x;kÞðyi    y;kÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
f
P
i2Ckðxi    x;kÞ
2gf
P
i2Ckðyi    y;kÞ
2g
q :
WCOR: weighted absolute difference of two
correlation coefﬁcients
We modify Equation (1) into the following weighted form
to deal with the range bias between two classes:
sðX;YÞ¼cjr1   r2jð 2Þ
We here describe how we can compute c of Equation (2).
The problem is to ﬁnd a gene pair with a high bias (dif-
ference) in the range of expression values between two
classes and then to discard it. To check the range of ex-
pression values, we can employ the variances, i.e. biweight
midvariances, qx,k and qy,k for class Ck. We can say that
the range of values is small if both qx,k and qy,k are small in
class Ck. Thus, for class Ck we can keep the maximum of
qx,k and qy,k, and if this value is small, we can see that the
range is small. The range bias can then be checked by the
ratio of the range (the maximum variance) of one class to
that of the other. In summary, we can ﬁrst take the
maximum of qx,k and qy,k for each class Ck and then
take the ratio of the maximum variance of one class to
that of the other class. Here, we note that the ratio can be
in two ways, i.e. the ratio of class 1 to class 2 and the ratio
of class 2 to class 1. We further note that Equation (2)
must become lower as the range bias increases more, and
so c in Equation (2) must take 1 for the case with no range
bias and be reduced to zero as the range bias increases.
Thus to make c hold this property, we can compute the
possible two ratios and take the minimum of the two
ratios.
Overall c can be given as follows:
c ¼ min
maxfqx;1;qy;1g
maxfqx;2;qy;2g
;
maxfqx;2;qy;2g
maxfqx;1;qy;1g
  
¼
the larger variance in class 1 ðor 2Þ
the larger variance in class 2 ðor 1Þ
:
ð3Þ
By using Equations (2) and (3), we can then compute
the score of each gene pair, indicating the possibility that
the gene expression of this pair can be a switching
mechanism. Then by computing scores of all possible
combinations of genes, WCOR can rank these combin-
ations by the computed scores.
ECOR: hypothesis testing for the equality of two
correlation coefﬁcients
The purpose of the hypothesis testing is to check the
equality of two correlation coefﬁcients (each being
derived from the corresponding one of two classes),
meaning that the hypotheses are H0:  1= 2 and H1:
 16¼ 2. Given the expression values of two genes with
two classes, if we assume that they take a bivariate
normal distribution for each class and the correlation
coefﬁcient is the Pearson’s correlation coefﬁcient for
each class, test statistic T of the likelihood ratio test for
H0 and H1 follows the chi-square distribution with one
degree of freedom under H0 (17,18):
T ¼
X 2
k¼1
Nk log
ð1   rk ^  Þ
2
ð1   r2
kÞð1   ^  2Þ
   2
1; ð4Þ
where ^   ð 1 < ^  <1Þ is a maximum likelihood estimator
for  1 and  2 under H0, where  1= 2, and ^   satisﬁes P2
k¼1 Nkðrk   ^  Þ=ð1   ^     rkÞ¼0. Interested readers
should see the Supplementary Data for the derivation of
Equation (4).
We apply this test statistic to the biweight midcorrela-
tion. More concretely, we use the biweight midcorrelation
given by Equation (2) for rk in Equation (4). We show the
empirical validation on this application of Equation (4)
to the biweight midcorrelation in the Supplementary
Data. We compute P-values by using this hypothesis
testing with the biweight midcorrelation. We can say
that two correlation coefﬁcients of pairs with higher
P-values than a speciﬁed signiﬁcance level are not different
statistically. Thus, out of the ranked list generated in
WCOR, ECOR removes pairs with higher P-values than
a pre-speciﬁed signiﬁcance level.
The entire procedure
Given an expression dataset with two classes, ROS-DET
ﬁrst generates all possible pairs of G genes. WCOR then
computes, for each of all pairs, the score given by Equation
(2), and further sorts all pairs according to the computed
scores. Finally, ECOR computes P-values of the sorted
pairs by using Equation (4) to remove pairs with higher
P-values than a preﬁxed signiﬁcance level. Figure 3 shows
a pseudocode of ROS-DET with WCOR and ECOR.
RESULTS
Validating WCOR (the ﬁrst step of ROS-DET)
with synthetic data
Experimental setting. The procedure of this experiment
is that we ﬁrst generate datasets according to some
distribution, changing its parameters, by which some
datasets are true positives and the rest are true negatives.
That is, the problem setting is binary classiﬁcation over
the generated datasets, i.e. predicting whether each dataset
is a positive or a negative. We then apply WCOR to this
problem and compare its performance with those of the
other competing methods.
For each dataset in class Ck, we generated examples
according to a bivariate g-and-h distribution with four
parameters, gk( 0), hk( 0),  k and  k (19) [More
concretely, we ﬁrst generated examples according to
bivariate normal distributions (for genes X and Y) and
transformed them into those in polar coordinates, in
which we used only the distance from the origin to each
example by which we generated examples following an
univariate g-and-h distribution. We show the detail of
generating the bivariate g-and-h distribution in the
Supplementary Data]. Here gk controls the skewness of
the distribution, and the distribution is symmetrical at
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meaning that this parameter had nothing to do with our
experiment. hk, a non-negative parameter, controls the
kurtosis (peakedness) of the distribution. We note that if
gk=hk=0, the distribution is the standard normal
distribution. As hk becomes larger, the distribution
becomes broader (or the distribution tail becomes more
emphasized), meaning that outliers can be generated more
easily.  k and  k are the variance of the distribution and
the (true) correlation coefﬁcient between two variates
(genes X and Y), respectively. We note that  k can be
used to generate the dataset with a different range
between genes X and Y. Under a ﬁxed hk, we change  k
and/or  k according to some manner, where under each
parameter setting, we generate a certain number of
datasets.
We tested three values of hk: 0, 0.5 and 1, ﬁxing
N1=N2=100. Under each of them, we changed  k
and/or  k in the following three types of manners:
(1) Randomness: under a certain hk, we generated
datasets, changing  k such that  1=  2=0,
0.01,...,1, ﬁxing  1= 2=1.  k=0 corresponds
to that of no correlations among examples in Ck,
while  k=1 corresponds to the state that examples
are totally correlated between two variates in Ck.
This means that examples are totally random when
 1=  2=0 and examples must be the switching
mechanism when  1=  2=1. Thus, datasets with
 1 and  2 closer to  1=  2=1 should be positives
and the rest should be negatives. In fact, we used  k
for rk in Equation (5), and ^   in Equation (5) can be
computed from each generated dataset, and then if
the P-value was less than the signiﬁcance level (5%),
we assigned ‘positive’ to the true class label of the
dataset; otherwise, ‘negative’ was assigned.
In prediction, we again emphasize that we used
WCOR only, in which we computed score s(X,Y)
in Equation (2) for each dataset and sorted all
datasets by scores.
We generated datasets 100 times for each pair of  1
and  2 and the results were averaged over total runs
under each setting.
(2) Range bias: under a certain hk, we generated data-
sets, changing the ratio of ranges (variances)
between two classes such that  2=1, 1.1,...,10,
ﬁxing  1=1 and  1=  2=0.5. Thus,  2=1
shows that the ratio is 1, while  2=10 shows that
the ratio is 10 (or 1
10). In this case, datasets with
lower  2 should be positives and those with higher
 2 should be negatives. The true class label is
assigned and predicted in a similar manner in the
previous experiment, but in true class label
assignment, we used the Bartlett test (20), which is
the hypothesis testing on the equality of four
different variances, to be generated in our case by
the combinations of two classes and genes X and
Y. We used the signiﬁcance level at 5% for the
P-value of the Bartlett test, meaning that a dataset
was positive if its P-value is higher than 5%. We
generated datasets 100 times for each  2 and the
results were averaged over total runs under each
setting.
(3) Randomness+Range bias: we changed both  k and
 k here so that  1=  2=0, 0.01,...,1,  2
1 ¼ 1a n d
 2
2 ¼ 1;1:1;...;10. To assign a class label to each
dataset, we used both Equation (4) and the Bartlett
test and regarded the datasets which were labeled as
positives by both of these two tests as positives and
the rest as negatives. We generated datasets 10 times
for each parameter setting and the results were
averaged over total runs under each hk.
For each of the above three settings, we show the
distribution of data points of representative samples in
the Supplementary Data.
Results. We evaluated the performance of each competing
method by using receiver operator characteristics (ROC)
curves. Figure 4 shows the average ROC curves of WCOR
(colored by red), being compared with those of four
competing methods: (i) the absolute difference of two
correlation coefﬁcients when using the Pearson’s
correlation coefﬁcient (Pearson), (ii) the Spearman’s
correlation coefﬁcient (Spearman), (iii) the (unweighted)
biweight midcorrelation (Biweight) and (iv) the interaction
Figure 3. Pseudocode of ROS-DET for detecting gene pairs which are
most likely to have switching mechanisms.
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for hk=0, 0.5 and 1.0, respectively, where outliers were
increased as hk increased. Figure 4a1 shows that all ROC
curves were lowered as increasing hk as shown by Figure
4a2 and a3 except those using robust correlation
coefﬁcients, i.e. WCOR, Spearman and Biweight,
implying that these methods were robust against
outliers. Figure 4b1–b3 show the results of Range bias
for hk=0, 0.5 and 1.0, respectively. These results show
that WCOR outperformed other competing methods
clearly, for any amount of outliers. In particular, the
performance advantage of WCOR over other methods
was clear in Figure 4b2 and b3, where the performances
of the other methods were almost on the diagonal line,
implying that their performances were similar to random
guessing while WCOR showed good performance by
showing a typical ROC curve. Figure 4c1–c3 show the
results of Randomness+Range bias, which is a more
real situation, for hk=0, 0.5 and 1.0, respectively. This
case, again, WCOR outperformed other four competing
methods clearly for all cases as shown by Range bias.
Overall, WCOR outperformed other methods in a more
Randomness
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Figure 4. ROC curves by WCOR (colored red), comparing those by interaction test (IT), the absolute difference between two Pearson’s correlation
coefﬁcients (Pearson), that between two Spearman’s correlation coefﬁcients (Spearman) and that between biweight midcorrelation coefﬁcients
(Biweight).
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as a comparable one to noise-robust methods, such as
the Spearman’s rank correlation and the biweight
midcorrelation. We run our experiments over the cases
with N1=N2=50 and N1=N2=20 and conﬁrmed
that the performance advantage of WCOR over other
competing methods was all kept, and this result is
attached to the Supplementary Data. Furthermore, we
checked the case with N1=N2=10 (shown in the
Supplementary Data), where however the advantage of
WCOR was not signiﬁcant but this case was mostly
removed by ECOR in real situations, implying that this
result will not affect the reliability of ROS-DET.
Validating ECOR (the second step of ROS-DET)
with real data
Experimental setting. Out of 2089 GEO DataSets (GDSs)
of the GEO database (21) of the latest update in July,
2008, we extracted 46 datasets (or GDSs) which satisfy
the following two conditions:
(1) Experimental conditions can be divided into two or
more classes.
(2) Each class has 10 or more experiments.
The 46 datasets are listed in the Supplementary Data.
Using the 46 datasets, ROS-DET ﬁrst generated
2.60 10
10 gene combinations. WCOR sorted out
2.60 10
10 pairs, according to the weighted absolute
difference of biweight midcorrelation. ECOR then
discarded gene pairs with P-values higher than a
preﬁxed threshold which was set to 1.92 10
 12.0.05/
(2.60 10
10) by considering the Bonferroni correction
and the signiﬁcance level of 5%. We used the Bonferroni
correction, which is known to be relatively conservative,
to keep reliable gene pairs only. The top 100 gene pairs by
ECOR, i.e. the ﬁnal output, is shown in the
Supplementary Data.
We ﬁrst compared the distribution of expression values
of the top 10 gene pairs by WCOR with that by ECOR.
We then focused on gene pairs, each being derived from a
GDS with, for each class, a certain number of replicates
(experiments) which we call ‘the number of examples’ or
‘sample size’. We showed the distribution (histogram)
of the number of examples, being generated by the top
1000 gene pairs by WCOR, comparing with those by the
original dataset and the top 1000 gene pairs by ECOR.
Results. Figure 5 shows expression values under two
experimental conditions (  and +) of the top 10 gene
pairs in the output of WCOR. This ﬁgure reveals that
the number of examples was very small for any gene
pair, by which some pairs cannot necessarily be switching
mechanisms. For example, the eighth ranked pair
consisted of three distant islands, which could not have
been a switching mechanisms, and the 10th ranked pair
had two non-overlapped distributions which also could
not have been a switching mechanism. On the other
hand, Figure 6 shows the top 10 gene pairs in the
output of ECOR. Each distribution of Figure 6 can be
seen as a switching mechanism more clearly than those
of Figure 5. This result indicates that the outputs of
WCOR were likely to be the cases with the smaller
number of examples, and ECOR works for removing
dubious cases in the outputs of WCOR.
Figure 7a shows the distribution of the number of
examples (sample sizes), by the original 46 datasets. This
distribution is rather uniform, meaning that 46 datasets
have a variety of sample sizes relatively equally, in the
range of 10–70. Figure 7b shows the distribution by the
top 1000 gene pairs obtained from WCOR. We here note
that the total sum of the number of all gene pairs in
(Figure 7b) is 2000 (=1000 2), since each gene pair
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Figure 5. Expression values of the top 10 gene pairs in the output of WCOR for real data.
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for each class. This ﬁgure clearly reveals that the top 1000
gene pairs by WCOR were so biased, where the number of
examples was all less than 20, being consistent with the
ﬁgures in Figure 5, all with only a small number of
examples. We then show that this bias can be relaxed by
ECOR. Figure 7c shows the distribution by the top 1000
gene pairs by ECOR, when we changed the cut-off value
for P-values from 10
 8 (Figure 7c1) to 10
 9 (Figure 7c2)
and further to 1.92 10
 12 (Figure 7c3) [Again note that
that the total sum of y-axis of Figure 7c1 and Figure 7c2
is equal to 2000 (=1000 2). Further, note that the
(a)( b)
10 20 30 40 50 60 70
7
8
9
1
0
1
1
1
2
Sample Size
l
o
g
1
0
(
#
p
a
i
r
s
)
10 20 30 40 50 60 70
0
.
0
1
.
0
2
.
0
3
.
0
Sample Size
l
o
g
1
0
(
#
p
a
i
r
s
)
(c1)( c2)( c3)
10 20 30 40 50 60 70
0
.
0
1
.
0
2
.
0
3
.
0
Sample Size
l
o
g
1
0
(
#
p
a
i
r
s
)
10 20 30 40 50 60 70
0
.
0
1
.
0
2
.
0
3
.
0
Sample Size
l
o
g
1
0
(
#
p
a
i
r
s
)
10 20 30 40 50 60 70
0
.
0
1
.
0
2
.
0
3
.
0
Sample Size
l
o
g
1
0
(
#
p
a
i
r
s
)
Figure 7. The log of #pairs, denoted by log10(#pairs) versus the number of examples, denoted by sample size, for (a) original data, (b) the top 1000
in the output of WCOR and (c) the top 1000 in the output of ECOR (ROS-DET), where the signiﬁcance level was set at (c1) 1.0e 8, (c2) 1.0e 9
and (c3) 1.92e 12, which was actually used in ROS-DET.
2.0 2.4 2.8
2
.
0
2
.
2
2
.
4
2
.
6
NSMCE4A
U
S
P
4
2.8 3.0 3.2 3.4 3.6
1
.
0
1
.
5
2
.
0
2
.
5
3
.
0
GANAB
H
S
3
S
T
1
3.65 3.75 3.85
2
.
0
2
.
2
2
.
4
2
.
6
ACTG1
L
I
T
A
F
1.0 1.5 2.0 2.5 3.0
2
.
4
2
.
6
2
.
8
3
.
0
3
.
2
HS3ST1
T
A
F
1
0
2.0 2.4 2.8
2
.
6
2
.
8
3
.
0
3
.
2
3
.
4
FARP1
N
O
N
O
0.0 0.4 0.8 1.2
0
.
0
0
.
5
1
.
0
1
.
5
GATAD2A
L
O
C
1
4
9
6
4
3
3.3 3.5 3.7 3.9
1
.
8
2
.
0
2
.
2
2
.
4
EZR
H
H
E
X
2.7 2.9 3.1
3
.
0
0
3
.
1
0
3
.
2
0
3
.
3
0
Ncl
P
r
k
c
b
1
2.0 2.4 2.8
1
.
5
2
.
0
2
.
5
ACAA1
E
P
H
X
2
2.2 2.4 2.6 2.8
2
.
0
2
.
5
3
.
0
3
.
5
INTS1
N
P
T
X
1
(a) 1st ranked (b) 2nd ranked (c) 3rd ranked (d) 4th ranked (e)
(f) (g)( h)( i)( j)
5th ranked
6th ranked 7th ranked 8th ranked 9th ranked 10th ranked
Figure 6. Expression values of the top 10 gene pairs in the output of ECOR, i.e. the ﬁnal output of ROS-DET, for real data.
e74 Nucleic Acids Research, 2011,Vol. 39,No. 11 PAGE 8 OF 14distribution of Figure 7c3 is shown by 191 gene pairs only,
which were all pairs obtained at this cut-off.]. The
distribution in Figure 7c1 was still biased and very
similar to Figure 7b, while that of Figure 7c2 was rather
similar to Figure 7a, meaning that the bias in Figure 7c1
was relaxed by lowering the cut-off value. Finally, Figure
7c3 also shows an uniform distribution, though the shape
is awkward because of the small number of gene pairs. We
note that Figure 7c3 was obtained by a systematic manner
in which we used the signiﬁcance level of 0.05 as a cut-off
value after applying the Bonferroni correction to P-values.
Overall, these results conﬁrmed that ECOR relaxed the
bias in the result of WCOR by removing dubious pairs.
Validating highly ranked gene pairs with the literature
Table 1 shows the information of the top 10 gene pairs
ranked by ROS-DET. For example,   and+in Figure 6
correspond to the left- and right-hand sides, respectively,
of annotations in Table 1. In Table 1, two genes of each
pair, say genes X and Y, have a clear switching mechanism
in gene expression, to be related with some biological
reason. Thus, we could make a pathway of genes that
connects genes X and Y, where each step of the pathway
would show a biological function like ‘binding’ or
‘positive regulation’. This case, one naturally arising
question is what biological system causes a switching
mechanism, i.e. that genes X and Y are correlated under
one condition and negatively correlated under the other
condition. This can be explained by the following
mechanism, which we call ‘parallel pathways’.
Parallel pathways. Parallel pathways are two pathways
which both reach (or start with) the same gene, which
we call the destination gene, and these pathways
satisfy the following two conditions: (i) gene X is in one
pathway and gene Y is in the other, and (ii) under one
experimental condition, genes X and Y are positively
correlated in expression (meaning that two pathways are
cooperatively used), and under the other experimental
condition, genes X and Y are negatively correlated in
expression (meaning that two pathways are alternatively
used). One possible scenario of a switching mechanism
with parallel pathways is that the expression of the
destination gene can be controlled by (or can control)
the two conditions. That is, the expression of the
destination gene can be changed by (or can change) the
cooperative or alternative expression of upstream (or
downstream) genes.
One typical example found by Li (5) has two genes, each
being in a different metabolic pathway from glutamate to
ornithine, controlled by the expression of CPA2, which is
in upstream of glutamate. That is, if the expression of
CPA2 is low, two genes are positively correlated in
expression, while if that of CPA2 is high, two genes are
negatively correlated, meaning that these two genes are
alternatively expressed.
Figure 8 illustrates a simulated example of two genes,
genes X and Y, with a switching mechanism and parallel
pathways, where gene Z is the destination gene. We
further note that genes X and Y must be correlated with
the gene Z in a particular manner: genes X and Y should
be both positively or negatively correlated with gene Z
under one condition (corresponding to + in Figure 8
showing both positive correlations), while genes X and
Y should be correlated with gene Z in two different
ways, i.e. one being positive and the other being
negative, under the other condition (corresponding to
  in Figure 8).
We here check how frequently the parallel pathways can
be found in the top 10 gene pairs ranked by ROS-DET
and further conﬁrm their validity by computing the
biweight midcorrelations between highly ranked paired
genes and the destination genes.
Top ranked gene pair. NSMCE4A [or NSE4A: non-SMC
element 4 homolog A (Saccharomyces cerevisiae)] and
USP4 (ubiquitin speciﬁc peptidase 4 or UNP) from
GDS2656.
NSMCE4A has a human homolog, NSE4B (or EID3).
The EID family has EID1, EID2 and EID3, in which both
EID1 and EID2 inhibit cell differentiation while both
Table 1. Detail of the top 10 gene pairs outputted from ROS-DET by using real data
Score P-value Gene pair GDS No. of examples
in classes 1 and 2
Annotation (Two classes:  /+)
1 1.710 1.56 10
 12 {NSMCE4A,USP4} GDS2656 14,14 Fetal/adult
2 1.688 2.77 10
 13 {HS3ST1,GANAB} GDS2545 18,25 Normal prostate tissue/
metastatic prostate tumor
3 1.684 1.30 10
 12 {ACTG1,LITAF} GDS1726 12,16 Control/HIV encephalopathy
4 1.639 8.29 10
 13 {HS3ST1,TAF10} GDS2545 18,25 Normal prostate tissue/
metastatic prostate tumor
5 1.606 1.31 10
 12 {FARP1,NONO} GDS2545 18,25 Normal prostate tissue/
metastatic prostate tumor
6 1.584 9.73 10
 13 {GATAD2A,LOC149643} GDS1917 14,14 Control/schizophrenia
7 1.581 2.68 10
 13 {EZR,HHEX} GDS1650 19,20 Adjacent normal/tumor
8 1.532 8.05 10
 13 {Ncl,Prkcb1} GDS1455 10,10 Medial motoneuron/
intermediolateral column motoneuron
9 1.522 3.66 10
 13 {ACAA1,EPHX2} GDS2545 18,25 Normal prostate tissue/
metastatic prostate tumor
10 1.488 1.64 10
 12 {INTS1,NPTX1} GDS963 18,18 Normal/macular degeneration
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of EP300 (22). This makes us assume that NSMCE4A
has the same biological function as EID1. EID1 interacts
with (probably binds to) MDM2 (23), which is a negative
regulator of tumor suppressor protein TP53 (24), implying
that MDM2 is rather a positive factor on tumor growth.
On the other hand, USP7, a ubiquitin speciﬁc peptidase
with the same function as USP4, stabilizes the activation
of TP53 (25), implying some negative effect on tumor
growth.
Figure 9 summarizes these genes into two parallel
pathways which both go to TP53. This ﬁgure shows a
direct implication to the mechanism between EID1 and
USP4 (or USP7), being consistent with parallel
pathways. Two conditions of GDS2656 are fetal and
adult. Figure 6a shows that two genes are positively
correlated under fetal while negatively correlated under
adult, implying that TP53 might be alternatively regulated
by NSMCE4A and USP4 under adult, while TP53 could
be regulated in a cooperative manner under fetal.
To conﬁrm this ﬁnding, we attempted to check the
expression of TP53 but we could not ﬁnd TP53 in
GDS2656, and so instead we checked the expression of
TP53RK, a TP53 regulating kinase. Table 2 shows the
biweight midcorrelation between TP53RK and each of
two genes of the top ranked pair. The result shows that
TP53RK is positively correlated with both NSMCE4A
and USP4 under fetal, while under adult, TP53RK is
positively and negatively correlated with NSMCE4A and
USP4, respectively. This result is consistent with our
ﬁnding, which implies cooperative regulation under fetal
and alternative regulation under adult.
We further checked the biweight midcorrelation
in expression between two neighboring genes which are
in the parallel pathways and indicated by positive or
negative regulation, e.g. negative regulation of MDM2
on TP53. We here note that we did not check neighboring
pairs labeled by ‘binding’, since binding is elusive by
including both positive and negative regulation. Thus,
the neighboring pairs we checked are MDM2 ! TP53
(negative regulation) and USP7 ! TP53 (positive
stabilization), and we used TP53RK instead of TP53.
Table 2 shows the result, indicating that under both fetal
and adult TP53RK was positively and negatively
correlated with MDM2 and USP7, respectively, which
are both reverse to the labels assigned to MDM2 !
TP53 and USP7 ! TP53. This implies that TP53RK
might be negatively regulated by TP53, and this ﬁnding
is consistent with (26). We note that even if TP53RK is
negatively regulated by TP53, it is not contradictory to
our ﬁnding that NSMCE4A and USP4 are cooperatively
correlated under fetal and are alternatively correlated
under adult.
Second ranked gene pair. HS3ST1 [heparan sulfate
(glucosamine) 3-O-sulfotransferase 1] and GANAB
(a-glucosidase) from GDS2545.
Both of these two genes are related with generating
glycans (27,28). HS3ST1 is involved with cancer cells
(28–30), while GANAB is related with carbohydrate
absorption and digestion, especially metastatic process
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Figure 8. Switching mechanism with parallel pathways.
Table 2. Biweight midcorrelations in gene expression of the top
ranked pair
Gene 1 Gene 2 r1( : Fetal) r2 (+: Adult)
NSMCE4A TP53RK 0.25 0.50
USP4 TP53RK 0.25  0.48
MDM2 TP53RK 0.35 0.40
USP7 TP53RK  0.27  0.40
binding same family negative regulation
positive stabilization
same function
homolog
EID1 MDM2
USP7
NSMCE4A EID3
TP53
USP4
Figure 9. Pathways for the top ranked gene pair.
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cyclophellitol and castanospermine, inhibit experimental
metastasis of tumor and tumor growth (31,32), meaning
that GANAB may be rather an activator for tumor
(metastasis), since these two GANAB inhibitors prevent
tumor growth. GANAB stably interacts with (probably
binds to) the external domain of PTPRC (CD45) (33),
where Lck is completely dysfunctional in the absence of
CD45 (34), and CD44 binds to Lck (35). On the other
hand, HS3ST1 activates anticoagulant heparan sulfate
(HS) (36) and can elevate the level of anticoagulant HS
(37). Anticoagulant HS binds to FGFR2 (36), which
further binds to FGF1 to produce a protein complex
(38). FGF1 binds to HSPA9 (39), which binds to TP53
(40), an inhibitor of CD44 (41). CD44 selectively
associates with active Lck, meaning that CD44 and Lck
can form a complex.
Figure 10 summarizes these relations into parallel
pathways both reach to the complex of CD44 and Lck.
Two classes of GDS2545 are normal tissues and prostate
tumor tissues. Figure 6b shows that GANAB and HS3ST1
are negatively correlated in expression under normal
tissues, while they are positively correlated under tumor
tissues. Here, TP53 is the inhibitor of CD44 in the
pathway, by which some switching mechanism might be
generated between GANAB and HS3ST1. That is, under
normal tissues, the negative correlation between GANAB
and HS3ST1 might lead to Lck and CD44 being highly
expressed when the expression of one of HS3ST1 and
GANAB is high (and the other is low). On the other
hand, under tumor tissues, the correlation in expression
between GANAB and HS3ST1 might indicate that the
expression of CD44 and Lck is not well balanced. For
example, even if both GANAB and HS3ST1 are well
expressed, one of CD44 and Lck might be poorly
expressed despite of the high expression of the other,
which might be a result of the disorder, i.e. prostate
tumor. To conﬁrm this inference, we checked the
biweight midcorrelation in expression between each gene
of the second ranked pair and Lck (and CD44). Table 3
shows that under normal tissues Lck (and CD44) is
correlated negatively and positively with GANAB and
HS3ST1, respectively, implying that both CD44 and Lck
can be expressed well when HST3ST1 is expressed highly
and GANAB is expressed poorly. On the other hand,
under tumor tissues, the expression of CD44 and Lck is
unbalanced under any situation in expression of GANAB
and HS3ST1. This result is clearly consistent with the
above inference.
We further checked the biweight midcorrelation
of neighboring two genes, which are in the parallel
pathways and expected to be positively or negatively
coexpressed. Again we did not check pairs labeled by
‘binding’, since binding includes both positive and
negative regulation. We then checked CD45 ! Lck
(coexpression) and TP53 ! CD44 (inhibitor). Table 3
shows that under tumor tissues, CD45 and Lck are
positively correlated and TP53 and CD44 are negatively
correlated, being consistent with the labels assigned to
these two edges in Figure 10.
Third ranked gene pair use. ACTG1 (actin gamma 1) and
LITAF [lipopolysaccharide-induced tumor necrorosis
factor (TNF)-a factor] from GDS1726.
LITAF activates the production of infection-ﬁghting
substance called TNF-a. Both ACTG1 and TNF can be
found in a HIV pathway (42), where TNF is an upstream
signal while ACTG1 appears in downstream. In fact, the
two experimental conditions measured in GDS1726 are
the HIV encelophathy and its control. This pathway
appears in the apoptosis pathway of KEGG. Figure 11
shows the two corresponding pathways. In both of these
pathways, simply LITAF or TNF is in upstream and
ACTG1 is in downstream, implying that this pair is not
parallel pathways, but TNF and ACTG1 were connected
by two different pathways, implying that this pair might
be explained by another parallel association, which might
cause a switching mechanism.
Fourth ranked gene pair. HS3ST1 [heparan sulfate
(glucosamine) 3-O-sulfotransferase 1] and TAF10 [RNA
polymerase II and TATA box binding protein (TBP)-
associated factor] from GDS2545.
coexpression
binding
binding
inhibitor binding binding binding activating binding
CD45
LCK
CD44 TP53 HSPA9 FGF1
GANAB
HS3ST1 FGFR2 anticoagulant
         HS
Figure 10. Pathways for the second ranked gene pair.
Table 3. Biweight midcorrelations in gene expression of the second
ranked pair
Gene 1 Gene 2 r1( : Normal) r2 (+: Tumor)
GANAB Lck  0.38  0.44
HS3ST1 CD44 0.28 0.34
HS3ST1 Lck 0.24  0.47
CD45 Lck  0.12 0.55
TP53 CD44 0.50  0.40
HIV pathway in BioCarta
activate
MAP3k RIPK1 TRAF1 ACTG1 CASP6 LITAF TNF TNFRSF1
Apoptosis pathway in KEGG
TRADD CASP8 CASP3
activate
LITAF TNF TNFRSF1 ACTG1 CASP6
Figure 11. Pathways for the third ranked pair.
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ranked gene pair. We can then use the same pathway as
that of the second ranked gene pair, and TP53 binds to
a TBP and represses its transcription (43). On the
other hand, TAF10 forms a complex (TFIID) with TBP
and other proteins, where TAF10 is important for
stabilizing the complex. We can summarize these genes
into Figure 12, which shows that HS3ST1 and TAF10
have parallel pathways. Two conditions of GDS2545 are
normal tissues and prostate tumor tissues. Figure 6d
shows that TAF10 and HS3ST1 are negatively correlated
in expression under normal tissues, while they are
positively correlated under tumor tissues. Here, TP53
represses transcription of TBP, with which TAF10 forms
a complex, by which under normal tissues, the negative
correlation between TAF10 and HS3ST1 might indicate
that both TBP and TAF10 are highly expressed when the
expression of HS3ST1 is low (and that of TAF10 is high),
while they are both not expressed highly when the
expression of HS3ST1 is high (and that of TAF10 is
low). On the other hand, under tumor tissues, the
expression of TAF10 and that of HS3ST1 are positively
correlated, possibly implying that the balance in
expression between TBP and TAF10 (by which a
complex will be formed) is not kept well, maybe because
of the disorder, i.e. prostate tumor. In order to conﬁrm
this inference, we checked the biweight midcorrelation
between TBP and two genes in the fourth ranked pair,
and Table 4 shows the result. From this table, we can
see that under normal tissues, TBP is negatively and
positively correlated with HS3ST1 and TAF10,
respectively, being consistent with our scenario. That is,
under normal tissues, both TBP and TAF10 can be
expressed highly when HS3ST1 is not expressed well,
while TBP and TAF10 will not be expressed highly if
HS3ST1 is expressed well. On the other hand, under
tumor tissues, TBP can be positively correlated with
both HS3ST1 and TAF10, although the correlation
values are relatively slight, indicating that the above
scenario or mechanism under normal tissues would not
work well under tumor tissues.
We further checked the biweight midcorrelation
between two neighboring genes, being labeled by
positive or negative regulation (as mentioned earlier,
we did not check those labeled by ‘binding’). We then
checked TP53!TBP (transcription repression) (since
anticoagulant HS is a chemical compound and not in
GDS2545). Table 4 shows the biweight midcorrelation
between TP53 and TBP, indicating negative correlation
under both normal and tumor tissues, which is consistent
with the fact that TP53 represses TBP.
Fifth ranked gene pair. FARP1 [FERM RhoGEF
(ARHGEF) and pleckstrin domain protein] and NONO
(non-POU domain containing octamer-binding) from
GDS2545.
NONO is deeply involved with human diseases, being a
cause of cell carcinoma by a translocation with TFE3.
TFE3 binds to a tumor suppressor p68 (DDX5) (44),
which binds to EP300 (45), which further binds to TP53
(46). TP53 is an inhibitor of CD44 (41). On the other
hand, CD44 forms a complex with ezrin family proteins
(47). FARP1 has three domains including an ezrin-like
domain. Figure 13 summarizes these genes into
pathways which have CD44 as their ﬁnal destination,
indicating parallel pathways. Two classes are normal
tissues and prostate tumor tissues, which are the same
as those of the second and fourth ranked gene pairs.
Figure 6e shows that NONO and FAPR1 are positively
correlated in expression under normal tissues, while they
are negatively correlated under tumor tissues, which is
reverse against the second and fourth ranked gene pairs.
However, these pathways are totally different from the
second and fourth pathways, except TP53 ! CD44, and
so these pathways might explain the switching mechanism
of FARP1 and NONO. Table 5 shows the biweight
midcorrelation between CD44 and each of the two genes
in this pair. From the table, we can see that under normal
tissues CD44 is positively correlated with both NONO
and FAPR1, while under tumor tissues CD44 is positively
and negatively correlated with NONO and FAPR1,
respectively. This result is consistent with our ﬁnding
that NONO and FAPR are cooperatively expressed
under normal tissues while they are alternatively expressed
under tumor tissues.
binding activating binding binding
binding
transcriptional
   repression binding
anticougulant
         HS
FGF1
TAF10
HS3ST1 FGFR2
TBA
TP53 HSPA9
Figure 12. Pathways for the fourth ranked gene pair.
Table 4. Biweight midcorrelations in gene expression of the fourth
ranked pair
Gene 1 Gene 2 r1( : Normal) r2 (+: Tumor)
HS3ST1 TBP  0.46 0.18
TAF10 TBP 0.43 0.26
TP53 TBP  0.59  0.33
forming
complex
inhibitor
domain
binding binding translocation binding
CD44
EZR
p68
FAPR1
TFE3 EP300 TP53 NONO
Figure 13. Pathways for the ﬁfth ranked gene pair.
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two neighboring genes which are in the pathway and not
shown by ‘binding’ and related labels. We then checked
TP53 ! CD44 (inhibitor) and FAPR1 ! EZR (domain).
The results are shown in Table 5, in which TP53 and
CD44 are negatively correlated under tumor tissues and
EZR and FAPR1 are positively correlated under both two
conditions. This result is also consistent with the labels
assigned to these neighboring genes.
Overall, to keep a switching mechanism with parallel
pathways, two genes in each pair should have the
following correlation with the destination gene. Two
paired genes are both positively or negatively correlated
with the destination gene under one condition, while
under the other condition, two paired genes are correlated
with the destination gene in two different ways, i.e. one
being positive and the other being negative. In fact, all
four pairs, i.e. the top, second, fourth and ﬁfth ranked
gene pairs have such correlations. This result also
implies that the switching mechanisms found by ROS-
DET are reliable.
The detail of the sixth to 10th ranked gene pairs is
shown in the Supplementary Data due to space
limitations. We found that each of the seventh to 10th
gene pairs has parallel pathways, meaning that totally
eight out of the top 10 gene pairs had parallel pathways.
DISCUSSION AND CONCLUSION
We have developed an efﬁcient and robust method,
ROS-DET, for detecting switching mechanisms in gene
expression. ROS-DET clearly outperformed current
approaches in a variety of experimental settings.
Particularly under the case of expression values with a
very small range, where the performance of all competing
methods was almost equal to random guessing, ROS-DET
achieved a signiﬁcantly better accuracy. We examined the
literature on the top ﬁve pairs ranked by ROS-DET and
found that each pair has been involved with a biological
pathway, which can connect two genes of the pair.
Furthermore, four out of the top ﬁve pairs have parallel
pathways, which were suggested by Li (5) as a typical case
of switching mechanisms, implying that four pairs have
real switching mechanisms. A possible explanation on
the parallel pathways which come to (or start with) the
destination gene is that the destination gene controls
(or is controlled by) two cases: two pathways are
cooperatively (or positively) correlated or two pathways
are alternatively (or negatively) correlated. In fact, in each
of all four pairs, the biweight midcorrelation between the
destination gene and two genes in the pair was consistent
with the above explanation. This result also supports
the performance of ROS-DET in detecting switching
mechanisms in gene expression.
Although the real computation time is not shown in our
experimental results, ROS-DET is very time efﬁcient,
because the time complexity of computing the biweight
midcorrelation coefﬁcient is totally the same as that of
a simple correlation coefﬁcient, such as the Pearson’s
correlation coefﬁcient.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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